drugset / Trial / NCT02937168

An Imaging Study Using PET/CT to Characterize the Effect of Intravenous Reslizumab on Airway Inflammation

NCT02937168

Phase 4 Terminated 5 enrolled Teva Branded Pharmaceutical Products R&D, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is an exploratory study with the following primary objectives: 1) to establish that PET/CT of the lung can reliably distinguish healthy, non-asthmatic participants from participants with severe asthma and an eosinophilic phenotype and 2) to examine the utility of PET/CT for demonstrating that reslizumab produces a reduction in lung inflammation in participants with severe asthma and an eosinophilic phenotype .

Timeline

Start
2017-05-08
Primary completion
2017-05-24
Completion
2017-05-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Reslizumab Monoclonal antibody 3 mg/kg Intravenous

Indications